UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 813

Sortiert nach

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2009-04, Vol.94 (4), p.1236-1243

2009

Volltextzugriff (PDF)

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

Nature reviews. Drug discovery, 2009-05, Vol.8 (5), p.369-385

Ahrén, Bo

2009

Volltextzugriff (PDF)

Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy

Endocrinology (Philadelphia), 2023-11, Vol.164 (12)

Ahrén, Bo

2023

Volltextzugriff (PDF)

Glucagon – Early breakthroughs and recent discoveries

Peptides (New York, N.Y. : 1980), 2015-05, Vol.67, p.74-81

Ahrén, Bo

2015

Volltextzugriff (PDF)

Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men

The journal of clinical endocrinology and metabolism, 2010-02, Vol.95 (2), p.872-878

2010

Volltextzugriff (PDF)

DPP-4 Inhibition and the Path to Clinical Proof

Frontiers in endocrinology (Lausanne), 2019-06, Vol.10 (JUN), p.376-376

Ahrén, Bo

2019

Volltextzugriff (PDF)

The Cephalic Insulin Response to Meal Ingestion in Humans Is Dependent on Both Cholinergic and Noncholinergic Mechanisms and Is Important for Postprandial Glycemia

Diabetes (New York, N.Y.), 2001-05, Vol.50 (5), p.1030-1038

2001

Volltextzugriff (PDF)

Gut peptides and type 2 diabetes mellitus treatment

Current diabetes reports, 2003-10, Vol.3 (5), p.365-372

Ahrén, Bo

2003

Volltextzugriff (PDF)

Dose-Dependent Inhibition by Ghrelin of Insulin Secretion in the Mouse

Endocrinology (Philadelphia), 2003-03, Vol.144 (3), p.916-921

2003

Volltextzugriff (PDF)

Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice

Peptides (New York, N.Y. : 1980), 2021-12, Vol.146, p.170650-170650, Article 170650

Ahrén, Bo

2021

Volltextzugriff (PDF)

Neuropeptides and the Regulation of Islet Function

Diabetes (New York, N.Y.), 2006-12, Vol.55 (Supplement 2), p.S98-S107

2006

Volltextzugriff (PDF)

Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors

Diabetes (New York, N.Y.), 2014-07, Vol.63 (7), p.2196-2202

2014

Volltextzugriff (PDF)

Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications

Diabetes care, 2007-06, Vol.30 (6), p.1344-1350

AHREN, Bo

2007

Volltextzugriff (PDF)

GLP-1 for type 2 diabetes

Experimental cell research, 2011-05, Vol.317 (9), p.1239-1245

Ahrén, Bo

2011

Volltextzugriff (PDF)

Inhibition of Dipeptidyl Peptidase-4 Augments Insulin Secretion in Response to Exogenously Administered Glucagon-Like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Gastrin-Releasing Peptide in Mice

Endocrinology (Philadelphia), 2005-04, Vol.146 (4), p.2055-2059

2005

Volltextzugriff (PDF)

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development

Journal of diabetes investigation, 2019-03, Vol.10 (2), p.196-201

Ahrén, Bo

2019

Volltextzugriff (PDF)

Physiology of incretins in health and disease

The review of diabetic studies, 2011, Vol.8 (3), p.293-306

2011

Volltextzugriff (PDF)

Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

Diabetologia, 2023-10, Vol.66 (10), p.1796-1808

2023

Volltextzugriff (PDF)

Glucose‐dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice

Journal of diabetes investigation, 2022-10, Vol.13 (10), p.1655-1665

Ahrén, Bo

2022

Volltextzugriff (PDF)

Insulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects

Diabetes care, 2007-03, Vol.30 (3), p.644-648

AHREN, Bo

2007

Volltextzugriff (PDF)

Differential Islet and Incretin Hormone Responses in Morning Versus Afternoon after Standardized Meal in Healthy Men

The journal of clinical endocrinology and metabolism, 2009-08, Vol.94 (8), p.2887-2892

2009

Volltextzugriff (PDF)

Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice

Endocrinology (Philadelphia), 2006-07, Vol.147 (7), p.3173-3180

2006

Volltextzugriff (PDF)

Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes

Metabolism, clinical and experimental, 2019-10, Vol.99, p.25-31

2019

Volltextzugriff (PDF)

The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice

Peptides (New York, N.Y. : 1980), 2024-01, Vol.171, p.171117-171117, Article 171117

2024

Volltextzugriff (PDF)

Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes

BioEssays, 1998-08, Vol.20 (8), p.642-651

Ahrén, Bo

1998

Volltextzugriff (PDF)

1 – 25 von 813

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(738)
Mit Volltextzugriff
(714)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy

Glucagon – Early breakthroughs and recent discoveries

Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men

DPP-4 Inhibition and the Path to Clinical Proof

The Cephalic Insulin Response to Meal Ingestion in Humans Is Dependent on Both Cholinergic and Noncholinergic Mechanisms and Is Important for Postprandial Glycemia

Gut peptides and type 2 diabetes mellitus treatment

Dose-Dependent Inhibition by Ghrelin of Insulin Secretion in the Mouse

Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice

Neuropeptides and the Regulation of Islet Function

Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors

Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications

GLP-1 for type 2 diabetes

Inhibition of Dipeptidyl Peptidase-4 Augments Insulin Secretion in Response to Exogenously Administered Glucagon-Like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Gastrin-Releasing Peptide in Mice

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development

Physiology of incretins in health and disease

Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

Glucose‐dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice

Insulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects

Differential Islet and Incretin Hormone Responses in Morning Versus Afternoon after Standardized Meal in Healthy Men

Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice

Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes

The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice

Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes

Suchergebnisse filtern